Summary

Lymphoma is a malignant tumor originated from the lymphatic hematopoietic system. It is mainly manifested as painless lymph node enlargement, hepatosplenomegaly, and all tissues and organs of the body can be affected, accompanied by fever, night sweats, emaciation, itching and other systemic symptoms. According to the tumor cells,it can be divided into two categories: non-Hodgkin’s lymphoma (NHL) and Hodgkin's lymphoma (HL). Pathological features in Hodgkin's lymphoma for tumor tissue contains lymphocytes, eosinophils, plasma cells and specificity in Reed-Steinberg cells, HL is classified into nodular lymphocyte-rich and classic type according to pathological type, the latter including lymphocytic type, nodular sclerosis type, mixed type cells and lymphocytes depletion type. The incidence of NHL is much higher than that of HL, and it is the sum total of a group of independent diseases with strong heterogeneity. Pathologically, NHL mainly consists of lymphocytes, histiocytes or reticular cells with different degrees of differentiation. According to the natural course of NHL, NHL can be classified into three clinical types, namely, highly invasive, invasive and inert lymphoma. Depending on the origin of lymphocyte, it can be divided into B cell, T cell and NK cell lymphoma.

LymphomaPlasma®

With advanced NGS technique, the solution is available for comprehensive testing on targeted genetic variation that is related to lymphoma and can be inhibited by medicine to offer clinical reference information for determining personalized therapeutic regimens for lymphoma patients. Burning Rock Dx has a patented automatic analysis reporting system and specialized medical departments. With a full range of software and hardware resources, it offers a full and accurate basis for doctors to make therapeutic decisions.

Applicable Populations

Lymphoma patients